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Predictors of Failure for Nonoperative
Management of Spinal Epidural Abscess
Sarah Hunter, MB ChB1,2 , Robert Cussen, MB BCh, BAO2,3,
and Joseph F. Baker, MCh, FRCSI1,2
Abstract
Study Design: Retrospective cohort study.
Objectives: The aim of this study is to identify predictive factors associated with failure of nonoperative management of spinal
epidural abscess (SEA).
Methods: Between January 2007 and January 2017, there were 97 patients 18 years or older treated for SEA at a tertiary referral
center. Of these, 58 were initially managed nonoperatively. Details on presenting complaint, laboratory parameters, radiographic
evaluation, demographics, comorbidities, and neurologic status (Frankel grades A-E) were collected. Success of treatment
was defined as eradication of infection with no requirement for further antimicrobial therapy. Diagnosis of SEA was made via
evaluation of imaging and intraoperative findings. Patients with repeat presentation of SEA, children, and those who were
transferred for immediate surgical decompression were excluded.
Results: Fifty-eight patients initially treated nonoperatively were included. Of these, 21 failed nonoperative management and
required surgical intervention. The mean age was 60 years, 66% male, and 19% of Maori ethnicity. Abscess location was pre-
dominantly dorsal, and in the lumbar region (53%). Multivariate analysis identified Maori ethnicity, multifocal sepsis, and elevated
white cell count as predictors of failure of nonoperative management. With 1 predictor the risk of failure was 44%. In the presence
of 2 predictive variables, failure rate increased to 60%, and if all 3 variables were present, patients had a 75% risk of failure.
Conclusion: Thirty-six percent of patients treated nonoperatively failed nonoperative management—the failure rate was sig-
nificantly increased in patients with multifocal sepsis, in patients with elevated white cell count, and in patients of Maori ethnicity.
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Introduction
Spinal epidural abscess (SEA) is potentially rapidly progres-
sive in its clinical course and is life-threatening.1 Left untreated
it can result in severe neurologic sequelae due to ischemic
necrosis of the neural elements.2,3 Due to a variety of factors
including, among others, the increasing use of immunosuppres-
sants, the increasing prevalence of diabetes, and increased age
of the population, the worldwide incidence of SEA has doubled
over the last 50 years.4
Known risk factors for SEA include diabetes mellitus, intra-
venous drug use (IVDU), immunosuppression, and alcohol
abuse.5 Early diagnosis of patients with acute spinal infection
is not necessarily straightforward—although a classic triad of
back pain, fever, and neurologic deficit is described, it is not
frequently captured in the primary care or emergency
department setting and a delay in diagnosis is common.5 Treat-
ment of SEA is dependent on a number of factors. The classic
approach to management that all SEA require urgent decom-
pression is challenged by recent literature.5,6 Well-reported
cohort studies have identified a range of factors that predict
failure of nonoperative management, such as diabetes and pre-
senting neurologic deficit.1,7,8
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New Zealand, with a unique multicultural society, has one
of the highest rates of invasive and noninvasive Staphylococcus
aureus infection in the developed world.9 The burden of dis-
ease following S aureus infection is disproportionately repre-
sented in indigenous populations, particularly Maori, Pacific,
and Aboriginal communities.10 It is estimated that two thirds of
spinal abscesses are caused by S aureus.5 The impact of this on
risk factors and prognostic variables for SEA within New Zeal-
and are uncertain.
Treatment with antibiotics and close clinical observation
needs to be balanced with timely identification of patients
likely to benefit from surgery; delayed operative manage-
ment can result in poor outcomes.1,4,5 Previously, factors
such as neurological deterioration, increased inflammatory
markers, and medical comorbidity have been statistically
associated with high risk of failure.11 Our article is the first
to explore ethnicity in association with medically treated
SEA.
The aim of this study was to identify factors associated with
failure of nonoperative management of SEA in a New Zealand
patient cohort.
Methods
Using hospital coding, we identified all patients who were
admitted with a diagnosis of SEA between January 2007 and
January 2017. The years were selected to allow confirmation of
the diagnosis using the digital radiographic record and to allow
calculation of 1-year mortality. Clinical Audit Support Unit
approval was granted for an outcome analysis.
Our hospital is a Level 1 trauma center and tertiary referral
spine center for a population of just over 900 000. Census data
from 2017 shows a diverse demographic with 74.1% New
Zealand European and 22.8% Maori; there is a relatively higher
proportion of Maori in our region than New Zealand as a whole
(15.7%).12
Inclusion criteria included the following: age >18 and
first presentation with SEA. Recurrent cases and surgical
site infections were excluded. Diagnosis was confirmed
based on radiological evidence with magnetic resonance
imaging (MRI).
For the purposes of this study, patients in the “nonoperative”
category were those patients with radiologically proven SEA
for whom the initial decision was to treat with antibiotic ther-
apy with or without radiologic drainage (N¼ 58). This decision
was taken by the initial treating team including spinal surgeons
and infectious disease physicians.
Failure of nonoperative management and the decision to
proceed to surgery was indicated by worsening neurology, or
lack of clinical improvement including failure of laboratory
markers to respond. Worsening neurology was defined by
increased weakness, sensory loss, or cord compromise with
supportive clinical examination findings. Palliative patients
who did not survive nonoperative treatment were not included
in the treatment failure group.
Data Collection
Explanatory variables and outcomes were collected retrospec-
tively. Demographic details, past medical history, concurrent
infection, and social factors were recorded. Information about
presenting complaint (pain, motor function, sensory function),
laboratory values (C-reactive protein [CRP], mg/L), white cell
count ([WCC] L), hemoglobin ([Hb] g/dL), albumin ([Alb],
mg/L), and microbiology (cultures) were reviewed. Neurologi-
cal function was scored with pre- and posttreatment Frankel
grade. For the purposes of this study, a patient with concurrent
infection such as pneumonia, psoas infection, or urinary tract
infection was defined as having “multifocal sepsis.” Details
from past medical history included established risk factors for
SEA: IVDU, immunosuppression, diabetes mellitus (DM),
renal disease, and liver disease.13 The diagnosis of DM was
validated with laboratory assessment of HbA1c where avail-
able. To capture the wider burden of disease the Charlson
Comorbidity Index (CCI) was calculated for each patient.
MRI reports were obtained to quantify the level and position
of the abscess relative to the thecal sac. Patients were fol-
lowed up for a minimum of 2 years.
Statistical Analysis
The 2 cohorts were represented by descriptive statistics; relative
frequencies, percentages, interquartile range, and mean/median
were calculated. Univariate analysis for descriptive statistics was
either t test (numerical variables) or Fisher’s exact test (catego-
rical variables). Bivariate and regression analysis was performed
on the data to identify potential predictors of failure. Bivariate
analysis was used to calculate odds ratios for all variables and
record statistical significance (P < .05). Stepwise backwards
regression analysis was performed to further examine potential
correlative predictors. Nonsignificant values were tested to avoid
overprediction. Power for multivariable modelling of 3 signifi-
cant values in multivariable regression is 0.98 (R2 ¼ 0.31).
Results
Over the 10-year period, 97 patients presented with sponta-
neous SEA and were considered eligible for inclusion in this
study. After assessment, 58 were initially treated nonopera-
tively. Overall, there were 39 males and 19 females; average
age was 63.1 years (range¼ 18-93 years). In terms of ethnicity,
there were 22% Maori and 78% non-Maori, figures that closely
align with ethnic breakdown for the region (Table 1).
Out of the 58 patients, 21 (36%) “failed” conservative
management and went on to require an operation. Reasons
given for converting to operative management included
worsening neurology (n ¼ 8, 38%), radiological progression
(n ¼ 7, 33%), clinical deterioration (n ¼ 4, 19%), or lack of
improvement in laboratory markers together with no clinical
improvement (n ¼ 2, 10%).
The classical triad of back pain, neurology, and fever was
seen in only 4 patients. Back pain was the most common
2 Global Spine Journal
presenting complaint (>65%). Forty-three percent of patients
had neurological symptoms and the majority had a fever
recorded on arrival (77%).
Positive blood cultures were retrieved from 44 patients. The
most common causative organism was S aureus (58.6%).
Methicillin-resistant Staphylococcus aureus was identified in
6 patients. In 10 patients, no organism could be isolated.
Interventional radiology was used to obtain samples from
8 patients. These patients were all being treated nonopera-
tively, and the abscess pattern on MRI was considered amen-
able to needle drainage by the radiologist and surgical team.
Patients without an organism isolated were treated with
broad spectrum antibiotics aiming to cover gram positive,
gram negative, and anaerobic organisms. Infectious disease
specialists advised on type and duration of antibiotic
treatment.
Abscess location was predominantly dorsal (>70%). Thirty-
one patients had abscesses in the lumbar region (31%), 10 were
thoracic (17%), 6 were cervical (10%), and 11 (19%) spanned
multiple levels.
For those patients with concurrent infection, most frequently
identified locations were chest (n ¼ 13, 22%) or intramuscular
infections, for example, psoas (n ¼ 14, 24%).
Common risk factors for the development of SEA seen in
our population were chronic kidney disease (17.2%) and immu-
nosuppression (15.5%).
Table 1. Descriptive Statisticsa.
Variable Nonoperative (N ¼ 37) Failed Nonoperative (N ¼ 21) Combined (N ¼ 58) P Values (Univariate)
Demographics
Mean age (IQR) 63.9 (27) 62.4 (21) 63.1 (25) .75
Male gender 27 (73%) 12 (57.1%) 39 (67%) .22
Maori 5 (13.5%) 7 (33.3%) 13 (22%) .24
Non-Maori 32 (86.5%) 14 (66.7%) 46 (79%) .09
NZ European 28 (75.7%) 14 (66.7%) 42 (72.4%) .54
Asian 2 (5%) 0 2 (3%) .53
Unstated 2 (5%) 0 2 (3%) .53
Presenting symptoms
Pain 35 (95%) 21 (100%) 56 (96%) .52
Radiculopathy 12 (32.4%) 8 (38.1%) 20 (34.5%) .78
Back pain 25 (67.6%) 14 (66.7%) 39 (67.2%) 1
Fever 27 (73%) 18 (85.7%) 45 (77.6%) .34
Neurology 13 (35.1%) 12 (57.1%) 25 (43%) .16
Frankel grade <E 7 (18.9%) 11 (52.4%) 18 (31%) .01*
Laboratory values
Mean white cell count 11.6 (5.7) 13.8 (9.8) 12.1 (6.8) .26
Mean C-reactive protein 154 (179.5) 174 (74) 161 (165) .30
Mean albumin 31.6 (6) 32.4 (10) 31.8 (7) .9
Mean hemoglobin 122 (28) 112 (75) 118 (28) .08
Positive blood culture 25 (65.8%) 19 (90.5%) 44 (75.9%) .06
Staphylococcus aureus 22 (57.9%) 12 (57.1%) 34 (58.6%) 1
MRSA 3 (8%) 3 (14.3%) 6 (10%) .66
Abscess characteristics
Lumbar 20 (52.6%) 11 (52.4%) 31 (53.4%) 1
Cervical 5 (13.2%) 1 (4.8%) 6 (10%) .40
Thoracic 7 (18.4%) 3 (14.3%) 10 (17.2%) .73
Multilevel 5 (12.2%) 6 (28.6%) 11 (19%) .18
Discitis/osteomyelitis 29 (76.3%) 19 (90%) 48 (82.8%) .30
Dorsal 27 (73.0%) 15 (71.4%) 42 (72.4%) 1
Ventral 14 (37.8%) 7 (33.3%) 21 (36.2%) .78
Medical comorbidities
Diabetes 3 (7.9%) 5 (23.8%) 8 (13.8%) .27
Immunosuppression 6 (15.8%) 3 (14.3%) 9 (15.5%) 1
Multifocal sepsis 21 (55.3%) 20 (95%) 41 (70.7%) .0001*
Liver disease 2 (5.3%) 4 (19%) 6 (10%) .18
Chronic kidney disease 7 (18.4%) 3 (14.3%) 10 (17.2%) .73
IV drug use 0 (0%) 3 (14.3%) 3 (5%) .04*
Mean Charleston Comorbidity Index 3.7 (4) 4 (3) 3.7 (4) .66
1 Year mortality 10 (26%) 4 (19%) 14 (24%) .75
Abbreviations: IQR, interquartile range; MRSA, Methicillin-resistant Staphylococcus aureus; IV, intravenous.
aData are mean values followed by interquartile range.
*Significant.
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Overall mortality at 1 year for the full cohort of 58 patients
was 24%. This includes 4 patients who converted to surgery
(19%) and 10 patients managed nonoperatively (26%).
Mortality between the 2 groups was not statistically different
(P ¼ .75).
When comparing patient characteristics in the “failure”
group and “successful” group, we identified some significant
differences. These were found using simple univariate analysis
with Fisher’s exact test and Student’s t test.
In the group that failed medical management, there were
significantly higher numbers of patients with a presenting neu-
rological defect (Frankel grade <E, P ¼ .01). The rates of
multifocal sepsis were also significantly different. Multifocal
sepsis was seen in 95% of the failure group and only 55% of the
nonoperative group (P ¼ .0001).
Mean WCC and CRP were also higher in the failure group,
13.8  103 cell/mL (SD 9.8) and 174 (mg/L) compared with
11.6  103 cell/mL (SD 5.7) and 154 (mg/L), respectively.
IVDU was seen in only 3 patients, all of whom were in the
failure group (P ¼ .04). This higher number of IV drug users is
likely related to sampling error.
There were no significant differences when considering
comorbidities. Both groups had a similar mean CCI (3.7 vs 4,
P ¼ .66).
We then performed a bivariate logistic regression to identify
explanatory variables of failure of nonoperative management
(Table 3). The odds ratios (ORs) were statistically significant
for Maori ethnicity (OR ¼ 14.2, P ¼ .03), WCC (OR ¼ 1.2, P
¼ .03), and multifocal sepsis (OR ¼ 110, P ¼ .05). This was
confirmed by repeating the regression analysis, with a back-
wards stepwise regression. IV drug use did not achieve statis-
tical significance in bivariate analysis (P ¼ .97) (Table 4).
Subgroup analysis to examine Maori versus non-Maori
patient characteristics did not reveal statistically significant
differences in burden of chronic disease or other patient demo-
graphics (Table 2). This was also done using Fisher’s exact test
or Student’s t test. However, in the full cohort of Maori patients
who had an organism isolated by either blood culture or radi-
ologic sampling, 88% of causative organisms were S aureus
(n ¼ 15/17).
Baseline rate of failure for medical management is high,
sitting at 25% without any predictive variables. The presence
of one factor raises it to 44% failure risk. When 2 factors are
present there is a 60% failure risk. With all 3 parameters,
patients showed a 75% failure risk for medical management.
Discussion
The consequences of irreversible neurologic impairment sec-
ondary to SEA are considerable for both individuals and com-
munities: 90% of patients with SEA who initially present with
Table 2. Subgroup Ethnicity Analysis.
Maori Non-Maori
n % n % Fishers’ Exact/t Testa
Total 7 14
Diabetes 1 14.3 4 28.6 .6
CKD 2 28.6 1 7.1 .25
Multifocal 5 71.4 13 92.9 .24
Liver disease 0 0.0 3 21.4 .52
CCI 3.7 4.1 .71
Mean age 64.9 61.1 .64
Neurology 4 57.1 8 57.1 1
Positive blood culture 5 71.4 14 100.0 .1
Ventral 1 14.3 6 42.9 .33
MRSA 1 14.3 2 14.3 1
Abbreviations: CKD, chronic kidney disease; CCI, Charlson Comorbidity
Index; MRSA, Methicillin-resistant Staphylococcus aureus.
aFischer’s exact for categorical variables; t test for numerical means; P < .05.
Table 3. Odds Ratios for Bivariate Logistic Regression.
Variable OR 95% CI P Value
Age 0.94 343 0.8-1.1 .309
Gender 0.33 421 0.02-4.6 .413
Maori ethnicity 14.24 165 1.2-172 .036*
Fever 0.69 937 0.04-11.4 .801
Back pain 1.34 353 0.1-17.2 .820
Neurology 6.24 422 0.01-3142 .563
Radiculopathy 1.98 425 0.03-124 .745
Frankel grade <E 0.57 365 0.001-172 .848
WCC 1.26 378 1.01-1.58 .039*
CRP 1.00 468 1.0-1.01 .353
Hemoglobin 0.9515 0.9-1.02 .164
Albumin 1.04 882 0.91-1.21 .518
Positive blood culture 6.04 584 0.2-183 .301
Multifocal sepsis 110.72 676 0.83-N/A .059*
Diabetes 1.57 909 0.08-33 .768
Immunosuppression 0.42 214 0.01-14 .631
IVD 109 102 837.26 285 NA .977
Liver disease 0.09 321 0.0006-13 .347
CKD 0.09 772 0.003-3.5 .204
Multilevel 0.47 791 0.02-9.4 .627
Osteomyelitis/discitis 8.19 348 0.11-639 .344
CCI 1.19 016 0.56-2.5 .652
MRSA 0.01 712 0.0001-2.8 .116
Ventral component 0.52 961 0.03-9.6 .667
Abbreviations: OR, odds ratio; CI, confidence interval; WCC, white cell count;
CRP, C-reactive protein; IVD, intravenous drug use; CKD, chronic kidney
disease; CCI, Charlson Comorbidity Index; MRSA, Methicillin-resistant Staphy-
lococcus aureus.
*Statistically significant; P ¼ .05.






Maori 0.30 305 0.13 212 0.26 296 2.29 377 .0258
WCC 0.02 288 0.01 052 0.25 134 2.17 459 .03 414
Multifocal sepsis 0.32 513 0.11 982 0.31 298 2.71 355 .00 896
IVD use 0.73 705 0.25 547 0.33 965 2.88 505 .00 565
Abbreviations: WCC, white cell count; IVD, intravenous drug use.
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motor weakness have posttreatment neurological deficits.14,15
It has been previously been established that these patients are
very likely to benefit from surgery.16,17 Neurologic impairment
at earliest stage is indicative of more aggressive disease.15
However, the other predictors for failure of nonoperative
approach remain a matter of debate. The largest study to date
of 367 patients managed nonoperatively found that pretreat-
ment neurologic status, DM, anatomical abscess characteris-
tics, and pathologic/compression fractures had strongest
predictive power for failure.15 Earlier studies by Kim et al and
Patel et al were in agreement regarding the impact of DM and
neurologic impairment, but highlighted factors such as age
and WCC in regression analysis.1,7 No recent publication
analyzing predictors of medical treatment failure included
ethnicity as a demographic variable.
Simple univariate analysis of presenting neurological dete-
rioration (classified as Frankel grade <E) and multifocal sepsis
both produced statistically significant results in our population.
In multivariable analysis, multifocal sepsis retained signifi-
cance along with WCC and Maori ethnicity.
Our findings suggest that multifocal sepsis, Maori ethnicity,
and elevated WCC be considered predictors for failure of med-
ical management. Despite the low numbers in our cohort, the
statistically significant effect was confirmed by both multivari-
ate and correlative regression analysis. A larger cohort could
indeed result in identification of other risk factors; however,
detecting ethnicity as a potential risk factor for treatment fail-
ure is a potentially important finding that has relevance for
other regions with unique indigenous populations.
The baseline rate of failure in the absence of predictive
variables is considerable at 25% but comparable to pooled
analysis in a meta-analysis of 12 studies showed 29.3% pro-
portion of failure in medically managed SEA.11 Overall this
indicates that our cohort results are keeping with internation-
ally recorded rates of nonoperative failure. With all 3 of the
predictive variables present the failure rate increased to 75%.
Comparatively, predictive variables identified in the research
by Patel et al gave a 76.9% total risk of failure and 8.3% base-
line risk. It is notable that these predictive variables can cause
significant failure risk in patients even without presenting neu-
rologic defect.
Maori are the indigenous people of New Zealand compris-
ing 712 000 people, 15.8% of the total New Zealand popula-
tion.12 Extensive research has been done on the rates of
S aureus infection, wound healing, and prognosis among the
Maori population in New Zealand, which identifies this group
as uniquely at risk.10 Even when standardizing for socioeco-
nomic status and comorbidity, poor health outcomes among
Maori are still of major concern.18 Burden of chronic disease
as measured by CCI or incidence of diabetes and other comor-
bidities do not differ greatly between the Maori and non-Maori
patients in our cohort. There is little research available regard-
ing impact of ethnicity on presentation and prognosis for epi-
dural abscess. A US study looking at predictive outcomes
following SEA found ethnicity was not associated with wor-
sened disability or death in African American patients.8
However, research from New Zealand indicates Maori are
more likely to be affected by S aureus infection, with worse
overall outcomes. The high rates of osteomyelitis and soft tis-
sue infection with S aureus have been described as a
“disturbing national trend” in association with uncommon clin-
ical and molecular epidemiology, perhaps as a result of relative
geographical isolation in the Southwest Pacific.9,10 Aboriginal
populations in Australia also experience inequitable outcomes
from treatable infections and the reasons for this are not yet
completely understood.19
Early operative input for this population group may prevent
long-term neurologic damage.20 In 2008, a retrospective study
of 42 patients characterized the presentation and referral pro-
cess for SEA in New Zealand.21 Sixty-seven percent of these
patients had S aureus isolated.21 This study did not investigate
management of SEA, and their catchment had a particularly
low proportion of Maori patients (<5%). Conversely, the catch-
ment area for our research study has a higher proportion of
Maori patients than the national average (22.9% vs 15.8%).12,22
In the broader clinical environment, Maori patients have
been shown to experience inequitable access to surgery—this
includes significant delays in operative management of breast
cancer and coronary artery bypass grafting.22,23 Not unlike
SEA, these are time-sensitive conditions with lower rates of
survival following treatment delay.23 Deprivation scores, dis-
tance from treatment facility, body mass index, and smoking
status have all been implicated in the prognostic gap between
Maori and non-Maori.18,22,23 A study on breast cancer con-
ducted at the same tertiary care center showed a greater pro-
portion of Maori patients were living in rural areas (>50 km
from the center), and that Maori patients were more likely to
experience a delay in diagnosis.21 It would be useful to exam-
ine these variables in future studies involving multicultural
population cohorts.
As with all retrospective studies, our study is limited by
inherent selection bias and is reliant on clinician documenta-
tion in the medical records. Diagnosis and decision making are
strongly influenced by intuitive heuristics.24 Furthermore, SEA
is commonly identified late or misidentified in up to 50% of
patients.1,15 The presentation of back pain with fever, which
accounts for 29 patients in our cohort, is easily ascribed to other
conditions such as osteomyelitis or soft tissue infection and so
with this variation in presentation some patients may be more
likely to fail what would otherwise be appropriate nonoperative
management.15 The full “triad” of back pain, fever, and neu-
rology was seen in only 4 patients (7%), suggesting absence of
neurology should not abate clinical suspicion of SEA. Another
limitation from this study is the heterogeneity in documentation
and work of multiple specialists over the 10-year period. This is
a somewhat inevitable challenge in retrospective analysis.
Importantly, this article does not draw any conclusion
regarding the efficacy of operative management; it only makes
comment on the characteristics of patients more likely to fail
medical treatment. Overall mortality did not differ statistically
between the 2 groups (26% vs 19%, P¼ .76). This is in keeping
with other international findings; research by Kim et al did not
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show statistically different mortality in medically versus surgi-
cally treated patients.7 Worldwide mortality from SEA is esti-
mated between 11% and 34%.7 Controversy exists between
smaller studies regarding the absolute change in motor function
achieved with surgical intervention. A recent meta-analysis
focused on neurological outcomes found no statistical differ-
ence between surgical and nonsurgical management.4
Conclusion
Despite the use a relatively small cohort, we identified Maori
ethnicity, white cell count, and multifocal sepsis as a signif-
icant predictors of failure of nonoperative management of
SEA. Prospective data collection will allow us to determine
whether other variables play a role in predicting treatment
failure. Ethnicity is a variable that must be considered in
treatment algorithms and models for spinal column infection
as it appears to be a potential risk factor. We recommend any
decision for nonoperative management be taken cautiously
given the high baseline rate of failure in both this study, and
the wider literature.25
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